Antisense Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase II clinical trial for the treatment of multiple sclerosis, Duchenne Muscular Dystrophy, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. Antisense Therapeutics Limited was incorporated in 2000 and is based in Toorak, Australia.
Show more...
CEO
Dr. James Garner B.Sc (Hons), B.Sc., M.A., M.A.I.C.D., M.B.A., MBA
Berapakah harga saham Antisense Therapeutics Limited hari ini?▼
Harga semasa ATHJF ialah $0.06 USD — telah meningkat sebanyak +0% dalam 24 jam yang lalu. Pantau prestasi harga saham Antisense Therapeutics Limited dengan lebih dekat pada carta.
Apakah simbol saham Antisense Therapeutics Limited?▼
Bergantung pada bursa, simbol saham mungkin berbeza. Sebagai contoh, di bursa , saham Antisense Therapeutics Limited didagangkan di bawah simbol ATHJF.
Berapakah hasil Antisense Therapeutics Limited untuk tahun lepas?▼
Hasil Antisense Therapeutics Limited untuk tahun lalu berjumlah 0 USD.
Berapakah pendapatan bersih Antisense Therapeutics Limited untuk tahun lepas?▼
Pendapatan bersih ATHJF untuk tahun lepas ialah -8.02M USD.
Antisense Therapeutics Limited terletak dalam sektor apa?▼
Antisense Therapeutics Limited beroperasi dalam sektor Health Care.